SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or the "Company")
announced today that it will focus the remaining patient enrollment of the
modified Phase IIb stroke trial in Canada and the U.S. and will no longer
recruit patients from India. As standard practice, the Drug Controller General
of India ("DCGI") limits the amount of patients that participate in clinical
trials from companies that are not located in India and SCT has been advised
that the stroke trial has reached its limit of recruiting patients from India. 


This decision by the DCGI was not based on any safety or mortality concerns. As
announced, the Data Safety Monitoring Board ("DSMB") completed three safety
analyses and recommended for the Phase IIb acute ischemic stroke trial to
continue as per protocol after each analysis. 


Dr. Alan Moore, President and CEO, commented as follows: 

"We have moved quickly through the modified REGENESIS Phase IIb stroke trial so
far, having enrolled 96 patients in six months, and we will now be focusing our
remaining patient recruitment efforts in Canada and the U.S. instead of India.
Given our historic recruiting rate in North America, it now appears unlikely
that we will able to complete the enrollment of 128 patients by the end of Q1
2010, as previously announced. We will also be reviewing alternate methods of
data analysis to possibly allow an earlier study conclusion prior to recruiting
the original goal of 128 patients."


About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public
biotechnology company (TSX VENTURE:SSS) focused on the development and
commercialization of drug-based therapies to treat central nervous system
diseases. SCT is a leader in the development of therapies that utilize drugs to
stimulate a patient's own resident stem cells. The Company's programs aim to
repair brain and nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual property supports
the potential expansion into future clinical programs in numerous neurological
diseases such as traumatic brain injury, multiple sclerosis, Huntington's
disease, Alzheimer's disease, and ALS.


For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com.


These securities have not been registered under the United States Securities Act
of 1933, as amended, or the securities laws of any state, and may not be offered
or sold within the United States or to, or for the account or benefit of U.S.
persons unless an applicable exemption from U.S. registration requirements is
available. 


Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024